(Bhagwat, A.M. et al (2004) A Randomized Double-Blind Clinical Trial to Investigate the Efficacy and Safety of ForsLean® in increasing Lean Body Mass Shri C. B. Patel Research Center for Chemistry and Biological Sciences, Mumbai, India)
In a randomized, double blind, 12 weeks study, 60 obese subjects received 250 mg of ForsLean® (25 mg forskolin) twice daily.
The volunteers receiving the ForsLean® on an average shed 1.73 kg or 4.02% of their total body weight, while the placebo group gained an average of 250 g (0.29%) of the total body weight. The difference in the weight and fat reduction was statistically significant between the active and placebo groups (Figure 4).
The thyroid function tests were performed, assessing levels of hormones T3, T4 and TSH before and after the completion of the study. It was observed that the levels of all three hormones remained within normal range in both active and placebo treated groups after 12 weeks of the regimen.
The blood lipid profile, performed at the onset and at the conclusion of the study, included triglycerides, total cholesterol, HDL, LDL and VLDL. Ratio of total cholesterol to HDL was also calculated. At the end of 12 weeks, the placebo treated volunteers did not show any significant change in any of the lipid parameters recorded. However, those volunteers on the active compound ForsLean® showed a significant rise in the concentrations of HDL at the end of the study, while triglycerides, total cholesterol, LDL and VLDL levels remained unchanged in this group as compared to baseline and placebo group levels.
Sabinsa Wins Again: Federal Court Denies Creative Compounds Motion
Listen to a brief video on ForsLean®
View past and recent advertisements
Innovative Ingredients Paper Weight loss approach
Sabinsa calls to readers' attention that some of the products, protocols and uses of the products described here in are or may be subject to various restrictions or limitations because of patents, exclusive or nonexclusive licenses, confidentiality agreements and other intellectual property or equivalent rights. Readers are advised to make an early and thorough investigation and inquiry into any product, protocol or use in which they may be interested, to see if any such rights might be applicable. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.